. home.aspx



GlaxoSmithKline's Nucala scores convenience boost with at-home dosing options

June 07, 2019 / Carly Helfand

GlaxoSmithKline’s Nucala has suffered against a more convenient AstraZeneca rival, but the company finally has an answer. Thursday, the FDA greenlighted two new delivery options for Nucala: an autoinjector and a prefilled syringe, both of which severe eosinophilic asthma patients can self-administer at home. “Choice is good for patients,” who will be able to decide with their doctors on either in-office or at-home dosing every four weeks, Sheri Mullen, senior vice president of GSK’s U.S. specialty business unit, said. Patients doctors deem eligible for an at-home option will go through training, either in the doctor’s office or on GSK’s website, Mullen said, adding that “it’s very simple and easy to use after that initial 1-2-3 step training.” And those who struggle to stay compliant or need more frequent doctor check-ins will still have the option to come in for dosing as they have in the past. “It very much is a shared decis...